Delaware Court Upholds Novartis’ Patent Exclusivity on Entresto, Blocking Generic Launch by MSN Pharmaceuticals

The legal battle over Novartis’ cardiovascular drug Entresto has reached a critical juncture with a decision from a Delaware federal judge. The judge denied MSN Pharmaceuticals Inc.’s effort to launch a generic version of Entresto by removing Novartis’ patent from the “Orange Book,” the federal database that lists patents linked to FDA-approved drugs. This move thwarts MSN Pharmaceuticals’ attempt to bring its generic product to market immediately, maintaining the exclusivity of Novartis’ patent protection. For further details on this legal decision, click here to read the Law360 coverage.